Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzagliatin vs Linagliptin in T2DM Patients With Moderate to Severe Chronic Renal Insufficiency
NCT07786571Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Randomised trial of dorzagliatin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Time in Range at 14 weeks. Planned start Dec 2026; status: withdrawn.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07786571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07786571.